Cyclacel Novel/Novel Sequence Promising In Tough Cancers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The combination of two novel drugs from Cyclacel inflicts a form of synthetic lethality in which sapacitabine causes DNA defects, rendering tumor cells vulnerable to seliciclib, which thwarts the repair process and is lethal in its own right, the lead investigator reported April 7 at the American Association for Cancer Research meeting in Washington, D.C.